Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, 11562 Cairo, Egypt.
Future Med Chem. 2018 Aug 1;10(16):1907-1924. doi: 10.4155/fmc-2018-0036. Epub 2018 Jul 3.
Discovery of novel series of colchicine binding site inhibitors (CBSIs).
MATERIALS & METHODS: Isoxazoline 3a-d, pyrazoline 4a-b, 7a-f and 8a-f, cyclohexenone 9a-b and 10a-b or pyridine derivatives 11a-b were synthesized and evaluated for their inhibition of tubulin polymerization and cytotoxicity. Most of the compounds displayed potent to moderate antitumor activity against leukemia SR cell line.7c, 7e and 11a were more potent than colchicine with IC of 0.09, 0.05 and 0.06 μM, and percentage inhibition in tubulin polymerization of 95.2, 96.0 and 96.3%, respectively. Compounds 7c and 11a showed cell-cycle arrest at G2/M phase and induced apoptosis and were able to bind the colchicine binding site of tubulin with comparable affinity to colchicine. Docking study showed that these compounds may interact with tubulin exploiting a binding cavity not commonly reported in the binding of CBSI.
Compounds 7c and 11a may be considered as promising CBSI based on their excellent activity and favorable drug likeness profile.
发现新型秋水仙碱结合位点抑制剂(CBSIs)系列。
合成了异恶唑啉 3a-d、吡唑啉 4a-b、7a-f 和 8a-f、环己烯酮 9a-b 和 10a-b 或吡啶衍生物 11a-b,并评估了它们对微管蛋白聚合和细胞毒性的抑制作用。大多数化合物对白血病 SR 细胞系表现出较强的抗肿瘤活性。7c、7e 和 11a 的活性比秋水仙碱更强,IC 分别为 0.09、0.05 和 0.06μM,对微管蛋白聚合的抑制率分别为 95.2%、96.0%和 96.3%。化合物 7c 和 11a 能使细胞周期停滞在 G2/M 期,并诱导细胞凋亡,能够与微管蛋白的秋水仙碱结合位点结合,与秋水仙碱的亲和力相当。对接研究表明,这些化合物可能通过利用结合 CBSI 中未常见报道的结合腔与微管蛋白相互作用。
化合物 7c 和 11a 可能因其出色的活性和良好的药物相似性而被视为有前途的 CBSI。